A short acute octreotide test for response prediction of long-term treatment with somatostatin analogues in acromegalic patients

Hormone and Metabolic Research

Volumn 40, Issue 6, 2008, Pages 422-426

  Halperin, I ^a   Nicolau, J ^a   Casamitjana, R ^a   Sesmilo, G ^a   Serra Prat, M ^b   Palomera, E ^b   Puig Domingo, M ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

^b HOSPITAL DE MATARÓ   (Spain)

Author keywords

Acromegaly; Drug treatment; Octreotide; Pituitary tumors

Indexed keywords

GROWTH HORMONE; LANREOTIDE LAR; OCTREOTIDE; OCTREOTIDE AUTOGEL; OCTREOTIDE LAR; SOMATOMEDIN C; SOMATOSTATIN DERIVATIVE;

ACROMEGALY; ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL DECISION MAKING; CORRELATION ANALYSIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; FEMALE; HUMAN; LONG TERM CARE; MALE; PREDICTION; PRIORITY JOURNAL; RELIABILITY; RETROSPECTIVE STUDY; SAMPLING; STATISTICAL SIGNIFICANCE; TIME; TREATMENT RESPONSE;

NUCLEOPOLYHEDROVIRUS;

EID: 47049107429     PISSN: 00185043     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2008-1065339     Document Type: Article

References (21)

1. Bevan JS, Atkin SL, Atkinson AB, Bouloux PM, Hanna F, Harris PE, James RA, MacConnell M, Roberts GA, Scanlon MF, Stewart PM, Teasdale E, Turner HE, Wass JA, WardlawJM. Primary medical therapy for acromegaly: an open, prospective, multicenter study of the effects of subcutaneous and intramuscular slow-release octreotide on growth hormone, insulin-like growth factor-I, and tumor size. J Clin Endocrinol Metab 2002; 87: 4554-4563
2. Freda PU. Somatostatin analogs in acromegaly. J Clin Endocrinol Metab 2002; 87: 3013-3018
3. Bevan JS. The antitumoral effects of somatostatin analog therapy in acromegaly. J Clin Endocrinol Metab 2006; 90: 1856-1863
4. Balsa JA, Varela C, Lucas T, Carcía-Vría J, Barceló B, Sancho-Rof JM. Varying additive effects of bromocriptine with two somatostatin analogs in cultures of GH-secreting adenomas. Horm Metab Res 2002; 34: 435-440
5. Clemmons DR, Chihara K, Freda PU, Ho KKY, Klibanski A, Melmed S, Shalet SM, Strasburger CJ, Trainer PJ, Thorner MO. Optimizing control of acromegaly: integrating a growth hormone receptor antagonist into the treatment algorithm. J Clin Endocrinol Metab 2003; 88: 4759-4767
6. Lamberts SW, Uitterlinden P, Schuijff PC, Klijn JC. Therapy of acromegaly with sandostatin: the predictive value of an acute test, the value of serum somatomedin-C measurements in dose adjustment and the definition of a biochemical 'cure'. Clin Endocrinol (Oxf) 1988; 29: 411-420
7. Colao A, Ferone D, Lastoria S, Marzullo P, Cerbone G, Di Sarno A, Longobardi S, Merola B, Salvatore M, Lombardi G. Prediction of efficacy of octreotide therapy in patients with acromegaly. J Clin Endocrinol Metab 1996; 81: 2356-2362
8. Lindsay JR, MacConnell EM, Hunter SJ, MacCance DR, Sheridan B, Atkinson AB. Poor responses to a test dose of subcutaneous octreotide predict the need for adjuvant therapy to achieve "safe" growth hormone levels. Pituitary 2004; 7: 139-144
9. Pokrajac A, Claridge AG, Shakoor SKA, Trainer PJ. The octreotide test dose is not a reliable predictor of subsequent response to somatostatin analogue therapy in patients with acromegaly. Eur J Endocrinol 2006; 154: 267-274
10. Herder WW de, Taal HR, Uitterlinden P, Feelders RA, Janssen JA, Lely AJ van der. Limited predictive value of an acute test with subcutaneous octreotide for long-term IGF1 normalization with Sandostatin LAR in acromegaly. Eur J Endocrinol 2005; 153: 67-71
11. Granada ML, Murillo J, Lucas A, Salinas I, Llopis MA, Castells I, Foz M, Sanmartí A. Diagnostic efficiency of serum IGF-I, IGF-binding protein-3 (IGFBP-3), IGF-I/IGFBP-3 molar ratio and urinary GH measurements in the diagnosis of adult GH deficiency: importance of an appropriate reference population. Eur J Endocrinol 2000; 142: 243-253
12. Melmed S, Casanueva FF, Cavagnini F, Chanson P, Frohman L, Grossman A, Ho K, Kleinberg D, Lamberts S, Laws E, Lombardi G, Vance ML, Werder KV, Wass J, Giustina A. Guidelines for acromegaly management. J Clin Endocrinol Metab 2002; 87: 4054-4058
13. Erturk E, Tuncel E, Kiyici S, Ersoy C, Duran C, Imamoglu S. Outcome of surgery for acromegaly performed by different surgeons: importance of surgical experience. Pituitary 2005; 8: 93-97
14. Reubi JC, Landoldt AM. The growth hormone responses to octreotide in acromegaly correlate with adenoma somatostatin receptor status. J Clin Endocrinol Metab 1989; 68: 844-850
15. Bhayana S, Booth GL, Asa SL, Kovacs K, Ezzat S. The implication of somatotroph adenoma phenotype to somatostatin analog responsiveness in acromegaly. J Clin Endocrinol Metab 2005; 90: 6290-6295
16. Jenkins PJ, Emery M, Howling SJ, Evanson J, Besser GM, Monson JP. Predicting therapeutic response and degree of pituitary tumour shrinkage during treatment of acromegaly with octreotide LAR. Horm Res 2004; 62: 227-232
17. Halah FPB, Elias LLK, Martinelli CE, Castro C, Moreira AC. Usefulness of subcutaneous or long-acting octreotide as a predictive test and in the treatment of acromegaly. Arq Bras Endocrinol Metabol 2004; 48: 245-252
18. Biermasz NR, Pereira AM, Smit JWA, Romijn JA, Roelfsema F. Intravenous octreotide test predicts the long term outcome of treatment with octreotide-long-acting repeatable in active acromegaly. Growth Horm IGF Res 2005; 15: 200-206
19. Karavitaki N, Botusant I, Radian S, Coculescu M, Turner HE, Wass JAH. The value of an acute octreotide suppression test in predicting long-term responses to depot somatostatin analogues in patients with active acromegaly. Clin Endocrinol (Oxf) 2005; 62: 282-288
20. Gilbert JA, Miell JP, Chambers SM, MacGregor AM, Aylwin SJ. The nadir growth hormone after an octreotide test predicts the long-term efficacy of somatostatin analogue therapy in acromegaly. Clin Endocrinol (Oxf) 2005; 62: 742-747
21. Lely AJ van der, Hutson RK, Trainer PJ, Besser GM, Barkan AL, Katznelson L, Klibanski A, Herman-Bonert V, Melmed S, Vance ML, Freda PU, Stewart PM, Friend KE, Clemmons DR, Johansson G, Stavrou S, Cook DM, Phillips LS, Strasburger CJ, Hackett S, Zib KA, Davis RJ, Scarlett JA, Thorner MO. Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist. Lancet 2001; 358: 1754-1759